ABOUT SUMMIT THERAPEUTICS

COMMITTED TO OPTIMIZING HUMAN HEALTH

LEADERSHIP

BOB DUGGAN
Chairman & CEO

CEO, Duggan Investments
Past Position: CEO, Pharmacyclics

Healthcare Visionary Multiple Insights of Magnitude Recipient of Multiple Leadership Awards

30+ Years Medical/Biotech

DR. MAKY ZANGANEH
CO-CEO & President Board Member

CEO, Dr. Maky Zanganeh & Associates
Past Position: COO, Pharmacyclics

Recipient of Multiple Leadership Awards in the Healthcare Industry

20+ Years Medical/Biotech

EXPERIENCED LEADERS AS HEADS OF DEPARTMENTS

- Will Black
- Dr. Betty Chang
- Dr. Fong Clow
- Ankur Dhingra
- Dr. Andy Dwyer
- Dave Gancarz
- Dr. Urte Gayko
- Campbell Hair
- Dr. Danelle James
- Shelley D Spray
- Dr. Elaine Stracker
- Dr. Juthamas Sukbuntherng

LOCATIONS

Offices in
Menlo Park CA
Oxford UK
Cambridge UK

Team Summit's executives have led fundamental paradigm shifts for the betterment of human health

Game-Changing Leadership Experience

STRATEGICALLY COMPELLING GLOBAL PARTNERSHIP

with an aligned mission - bringing ivonescimab to patients in need

Summit Therapeutics, Inc. has announced a definitive agreement of its partnership with Akeso Inc. (HKEX Code: 9926.HK, "Akeso"), to in-license its breakthrough bispecific antibody, ivonescimab. Akeso is a pioneer and source originator in developing innovative antibodies. The agreement supports Summit's mission of developing and commercializing groundbreaking oncology pipeline products aimed at improving the quality of life of patients with serious unmet medical needs. For Akeso, the deal represents an opportunity to introduce its highly innovative antibodies to markets, including the United States, Canada, Europe, and Japan – an important step towards Akeso's strategic intention of becoming a global biopharma organization.

Ivonescimab, known as AK112 in China and non-Summit territories, and also as SMT112 in the United States, Canada, Europe, and Japan (Summit License Territories), is a novel, potential first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking of VEGF into a single molecule. Ivonescimab is the most advanced PD-1/VEGF bispecific antibody in clinical development in the Summit License Territories: there are no known PD-1-based bispecific antibodies approved by the U.S. Food and Drug Administration ("FDA") or the European Medicines Agency ("EMA"). Ivonescimab was engineered to bring two well established oncology targeted mechanisms together.

SMT112
United States, Canada, Europe, Japan
(Summit License Territories)

AK112
China & Non-Summit Territories

Ivonescimab, is a novel, potential first-in-class PD-1/VEGF bispecific antibody

Summit is initiating development activities for SMT112 and will do so first in NSCLC indications. Summit plans to start treating patients in clinical studies by the second quarter of 2023.

Ivonescimab is an investigational therapy that is not approved by any regulatory authority. It is currently being investigated in Phase III clinical studies.

Contact
info@smmttx.com · investors@smmttx.com · media@smmttx.com

smmttx.com

162-010923